Cleveland Clinic is partnering with Human Longevity, Inc. (HLI) to first sequence and analyze blood samples from Cleveland Clinic’s GeneBank study of de-identified patients. As part of the agreement, the two organizations will apply whole genome, cancer and microbiome sequencing focusing on a subset of samples with the goal of discovering novel disease genes and disease pathways associated with heart disease.
“In medicine we are constantly exploring opportunities to better understand how diseases develop and what we can do to either prevent or provide the most impactful and effective course of treatment,” said Toby Cosgrove, M.D., President and CEO of Cleveland Clinic in a statement. “We are thrilled to be advancing the correlation of genomic data with clinical care.”
HLI is currently sequencing and analyzing thousands of whole genomes per month. The company is integrating this whole genome sequence data with extensive and unique clinical measures and imaging within the HLI Knowledgebase™. The combined high quality, comprehensive data will continue to enrich the HLI Knowledgebase™, which includes the company’s proprietary informatics analysis and data interpretation and integration. The company is pursuing agreements with a variety of customers including pharmaceutical and biotech companies, academic health systems, governments and insurers.
Founded in 2013, HLI is building the world’s most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. The company plans to license access to its database, and developing new diagnostics and therapeutics as part of their product offering.
Financial terms of the agreement were not disclosed.
